Vigil Neuroscience Announces Update On Its Small Molecule TREM2 Agonist Program; Company Expects To Receive Additional Details From FDA Within Next 30 Days; Will Work Closely With FDA To Address Partial Clinical Hold
Portfolio Pulse from Benzinga Newsdesk
Vigil Neuroscience (NASDAQ:VIGL) has announced VG-3927 as its lead candidate for the treatment of Alzheimer's Disease. The company's Investigational New Drug (IND) application for VG-3927 has been approved by the FDA, with a partial clinical hold related to maximum exposure limit. Phase 1 clinical trial in healthy volunteers is expected to commence in October 2023. The company will host a virtual R&D event on September 13, 2023, to highlight its small molecule TREM2 agonist program.
September 08, 2023 | 8:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vigil Neuroscience's IND application for VG-3927, a potential Alzheimer's treatment, has been approved by the FDA. The company expects to start Phase 1 clinical trial in October 2023 and does not anticipate any delays in the current clinical development plans.
The FDA's approval of the IND application for VG-3927 is a significant milestone for Vigil Neuroscience. This allows the company to proceed with the Phase 1 clinical trial, which is a crucial step in the drug development process. The company's confidence in not anticipating any delays in the current clinical development plans also indicates a positive outlook. Therefore, this news is likely to have a positive impact on the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100